万方数据
万方数据
万方数据
万方数据
万方数据
万方数据
万方数据
肿瘤个体化治疗的现状和前景
作者：韩晓红， 马丽， 石远凯， HAN Xiao-hong， MA Li， SHI Yuan-kai
作者单位：韩晓红,HAN Xiao-hong(100021,北京协和医学院,中国医学科学院肿瘤医院肿瘤研究所内科;100021,北京协和医学院,中国医学科学院肿瘤医院肿瘤研究所检验科)， 马丽,石远凯,MA
Li,SHI Yuan-kai(中国医学科学院肿瘤医院肿瘤研究所内科,北京协和医学院,100021)
刊名：
中华检验医学杂志
英文刊名：CHINESE JOURNAL OF LABORATORY MEDICINE
年，卷(期)：2011,34(4)
参考文献(35条)
1.Tomita M;Shimizu T;Ayabe T Prognostic significance of tumour marker index based on preoperative CEA and CYFRA 21-1 in non-small cell lung cancer 2010
2.He Q;Chen HY;Bai EQ Development of a multiplex methylight assay for the detection of multigene methylation in human colorectal cancer 2010
3.Maheswaran S;Sequist LV;Nagrath S Detection of mutations in EGFR in circulating lung-cancer cells 2008
4.Rosell R;Moran T;Queralt C Screening for epidermal growth factor receptor mutations in lung cancer 2009
5.Farzadnia M;Meibodi NT;Shandiz FH Evaluation of HER2/neu oncoprotein in serum and tissue samples
of women with breast cancer:correlation with clinicopathological parameters 2010
6.Barabási AL;Gulbahce N;Loscalzo J Network medicine:a network-based approach to human disease 2011
7.Toi M;Iwata H;Yamanaka T Clinical significance of the 21-gene signature (Oncotype DX) in hormone receptor-positive early stage primary breast cancer in the Japanese population 2010
8.Straver ME;Glas AM;Hannemann J The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer 2010
9.韩晓红;石远凯;马丽应用FISH和IHC技术检测中国乳腺癌患者HER-2基因状态及蛋白表达的前瞻性多中心研究[期刊论文]-中华检验医学杂志 2010(7)
10.Wang S;An T;Wang J Potential clinical significance of a plasmabased KRAS mutation analysis in patients with advanced non-small cell lung cancer 2010
11.van Oers MH;Van Glabbeke M;Giurgea L Rituximab maintenance treatment of relapsed/resistant follicular nonHodgkin's lymphoma:long-term outcome of the EORTC 20981 phase Ⅲ randomized intergroup study 2010
12.Delsol G Molecular abnormalities in lymphomas 2010
13.Schulz C;Heinemann V;Schalhorn A UGT1A1 gene polymorphism:impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorectal cancer 2009
14.Dempke WC;Heinemann V Ras mutational status is a biomarker for resistance to EGFR inhibitors in colorectal carcinoma 2010
15.McDermott U;Pusapati RV;Christensen JG Acquired resistance of non-small cell lung cancer cells to met kinase inhibition is mediated by a switch to epidermal growth factor receptor dependency 2010 16.Karp DD;Pollak MN;Cohen RB Safety,pharmacokinetics,and pharmacodynamics of the insulin-like
growth factor type 1 receptor inhibitor figitumumab (CP-751,871) in combination with paclitaxel and carboplatin 2009
17.Shaw AT;Yeap BY;Mino-Kenudson M Clinical features and outcome of patients with non-small-cell lung cancer who harbor EMI4-ALK 2009
18.Zhang X;Zhang S;Yang X Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression 2010
19.Yang C;shih J;Su W A phase Ⅱ study of BIBW 2992 in patients with adenocacinoma of the lung and activating EGFR mutations (LUX-Lung2) 2010(Suppl)
20.McDermott U;Settleman J Personalized cancer therapy with selective kinase inhibitors:an emerging paradigm in medical oncology 2009
21.Sève P;Dumontet C Is class Ⅲ beta-tubulin a predictive factor in patients receiving tubulin-binding agents 2008
22.Simon GR;Ismail-Khan R;Bepler G Nuclear excision repairbased personalized therapy for non-small cell lung cancer:from hypothesis to reality 2007
23.Olaussen KA;Fouret P;Kroemer G ERCC1-specific immunostaining in non-small-cell lung cancer 2007
24.Egawa C;Motomura K;Miyoshi Y Increased expression of BRCA1 mRNA predicts favorable response to anthracyclinecontaining chemotherapy in breast cancers 2003
25.Schindlbeck C;Mayr D;Olivier C Topoisomerase IIalpha expression rather than gene amplification predicts responsiveness of adjuvant anthracycline-based chemotherapy in women with primary breast cancer 2010
26.Gennari A;Sormani MP;Pronzato P HER2 status and efficacy of adjuvant anthracyclines in early breast cancer:a pooled analysis of randomized trials 2008
27.O'Shaughnessy J;Osborne C;Pippen JE Iniparib plns Chemotherapy in metastatic Triple-Negative Breast Cancer 2011
28.Schneider BP;Wang M;Radovich M Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer:ECOG 2100 2008
29.Burris HA 3rd;Rugo HS;Vukelja SJ Phase Ⅱ study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2) -positive breast cancer after prior HER2-directed therapy 2011
30.Scaltriti M;Chandarlapaty S;Prudkin L Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated
p95HER2 receptor 2010
31.Baselga J Treatment of HER2-overexpressing breast cancer 2010(Suppl 7)
32.Park S;Koo JS;Kim MS Androgen receptor expression is significantly associated with better outcomes in estrogen receptorpositive breast cancers 2011
33.Stendahl M;Nilsson S;Wigerup C p27 (Kipl) is a predictive factor for tarnoxifen treatment response but not a prognostic marker in premenopausal breast cancer patients 2010
34.Mok TS;Zhou Q;Leung L Personalized medicine for nonsmall-cell lung cancer 2010
35.储大同恶性肿瘤个体化治疗靶向药物的临床表现[期刊论文]-中华肿瘤杂志 2010(10)
本文链接：https://www.doczj.com/doc/6114066789.html,/Periodical_zhyxjy201104002.aspx